A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma
BJU International · 2024-02 · 133 (S3) · 57-67
DOI: 10.1111/bju.16190 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift BJU International, online erschienen am 20.11.2023. Verfasst von Ciara Conduit und 25 weiteren Autor:innen. Beteiligte Einrichtung: Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Renal Cell. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Bristol-Myers Squibb.
Abstract (Originalsprache)
Objective
To evaluate the efficacy of sequential treatment with ipilimumab and nivolumab following progression on nivolumab monotherapy in individuals with advanced, non‐clear‐cell renal cell carcinoma (nccRCC). Materials and Methods UNISoN (ANZUP1602; NCT03177239 ) was an open‐label, single‐arm, phase 2 clinical trial that recruited adults with immunotherapy‐naïve, advanced nccRCC. Participants received nivolumab 240 mg i.v. two‐weekly for up to 12 months (Part 1), followed by sequential addition of ipilimumab 1 mg/kg three‐weekly for four doses to nivolumab if disease progression occurred during treatment (Part 2). The primary endpoint was objective tumour response rate (OTRR) and secondary endpoints included duration of response (DOR), progression‐free (PFS) and overall survival (OS), and toxicity (treatment‐related adverse events).
Results
A total of 83 participants were eligible for Part 1, including people with papillary (37/83, 45%), chromophobe (15/83, 18%) and other nccRCC subtypes (31/83, 37%); 41 participants enrolled in Part 2. The median (range) follow‐up was 22 (16–30) months. In Part 1, the OTRR was 16.9% (95% confidence interval [CI] 9.5–26.7), the median DOR was 20.7 months (95% CI 3.7‐not reached) and the median PFS was 4.0 months (95% CI 3.6–7.4). Treatment‐related adverse events were reported in 71% of participants; 19% were grade 3 or 4. For participants who enrolled in Part 2, the OTRR was 10%; the median DOR was 13.5 months (95% CI 4.8–19.7) and the median PFS 2.6 months (95% CI 2.2–3.8). Treatment‐related adverse events occurred in 80% of these participants; 49% had grade 3, 4 or 5. The median OS was 24 months (95% CI 16–28) from time of enrolment in Part 1.
Conclusions
Nivolumab monotherapy had a modest effect overall, with a few participants experiencing a long DOR. Sequential combination immunotherapy by addition of ipilimumab in the context of disease progression to nivolumab in nccRCC is not supported by this study, with only a minority of participants benefiting from this strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Sydney, NSW, Australia.
- Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia.
- Eastern Health, Melbourne, VIC, Australia.
- Royal Brisbane and Women's Hospital, Herston, QLD, Australia.
- Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, SA, Australia.
- Macquarie University, Sydney, NSW, Australia.
ORCID-Profile: Ciara Conduit
Förderung
- Bristol-Myers Squibb
Zitieren
APA
Conduit, C., Davis, I. D., Goh, J. C., Kichenadasse, G., Gurney, H., Harris, C. A., Pook, D., Krieger, L., Parnis, F., Underhill, C., Adams, D., Roncolato, F., Joshua, A., Ferguson, T., Prithviraj, P., Morris, M., Harrison, M., Begbie, S., Hovey, E., …, & UNISoN Investigators (2024). A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma. BJU International, 133(S3), 57-67. https://doi.org/10.1111/bju.16190
Vancouver
Conduit C, Davis ID, Goh JC, Kichenadasse G, Gurney H, Harris CA, et al. A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma. BJU International. 2024;133(S3):57-67. doi:10.1111/bju.16190
BibTeX
@article{Conduit2024,
author = {Conduit, Ciara and Davis, Ian D and Goh, Jeffrey C and Kichenadasse, Ganessan and Gurney, Howard and Harris, Carole A and Pook, David and Krieger, Laurence and Parnis, Francis and Underhill, Craig and Adams, Diana and Roncolato, Felicia and Joshua, Anthony and Ferguson, Tom and Prithviraj, Prashanth and Morris, Michelle and Harrison, Michelle and Begbie, Stephen and Hovey, Elizabeth and George, Mathew and Liow, Elizabeth C and Link, Emma K and McJannett, Margaret and Gedye, Craig and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) and UNISoN Investigators, UNISoN Investigators},
title = {A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma},
journal = {BJU International},
year = {2024},
volume = {133},
number = {S3},
pages = {57--67},
doi = {10.1111/bju.16190}
}
EUVIMED